International Journal of Clinical Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Prognostic factors in cutaneous apocrine carcinoma: a single-institution retrospective study of 32 patients
ConclusionsSince CAC has a high rate of LN metastasis —and the number of LN metastases is a significant prognostic factor—LN evaluation should be considered for patients with CAC as initial treatment. Nonetheless, ≥ 4 LN metastases can be a poor prognostic factor for CAC. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - October 6, 2023 Category: Cancer & Oncology Source Type: research

Clinical course of longer than five years after definitive radiotherapy for nasopharyngeal carcinoma
ConclusionLate recurrences, severe late toxicities, and second primary cancers were observed  >  5 years after IMRT. A long-term follow-up of >  5 years is needed in patients with NPC. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - October 5, 2023 Category: Cancer & Oncology Source Type: research

Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan
ConclusionsThis is the first report to evaluate T-DXd-related ILD/pneumonitis cases in clinical practice. Our findings are consistent with previous reports and suggest that patients with DAD patterns have poor outcomes. Evaluation of a larger real-world dataset may further identify predictors of clinical outcome. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - October 3, 2023 Category: Cancer & Oncology Source Type: research

Intentions for catch-up HPV vaccination in Japan: an internet survey
ConclusionOur survey revealed that catch-up vaccination intentions differed depending on the vaccination environment.  It is necessary for all organizations involved with HPV vaccination, such as government, medical institutions, and educational institutions, to make recommendations based on an understanding of the characteristics of the “vaccinated generation” and the “vaccine-suspended generation”. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - September 30, 2023 Category: Cancer & Oncology Source Type: research

Risk of metachronous colorectal cancer after colectomy for first colon cancer in Lynch syndrome: multicenter retrospective study in Japan
ConclusionsTo reduce the incidence of mCRC, patients with genetically diagnosed LS and fCC, preferentially located in the left-sided colon, may need to undergo more extended colectomy than that usually performed in Japan. However, such extended colectomy should be counterbalanced with favorable overall survival and actual risk of mCRC development. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - September 26, 2023 Category: Cancer & Oncology Source Type: research

Preoperative prognostic model for localized and locally advanced renal cell carcinoma: Michinoku Japan Urological Cancer Study Group
ConclusionThe new preoperative prognostic model in LLRCC can be used in patient care and clinical trials. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - September 22, 2023 Category: Cancer & Oncology Source Type: research

Correction to: Circ_0000419 acts as a tumor suppressor in gastric cancer development via regulating miR ‑300/RGMB axis
(Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - September 13, 2023 Category: Cancer & Oncology Source Type: research

The predictive value of advanced lung cancer inflammation index for short-term outcomes and prognosis of colorectal cancer patients who underwent radical surgery
ConclusionLower ALI was associated with more postoperative complications, worse OS, and DFS for CRC patients who underwent radical surgery. Furthermore, ALI was an independent risk factor for overall complications, OS, and DFS. Surgeons should pay close attention to patients with low ALI before surgery and make clinical strategies cautiously. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - September 12, 2023 Category: Cancer & Oncology Source Type: research

Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1
(Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - September 9, 2023 Category: Cancer & Oncology Source Type: research

Can contralateral lymph-node metastases be ruled out in prostate cancer patients with only unilaterally positive prostate biopsy?
ConclusionOur study highlights the diagnostic value of bilateral pelvic lymphadenectomy and the need for careful planning in surgery for prostate cancer patients with unilaterally positive prostate biopsy. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - September 7, 2023 Category: Cancer & Oncology Source Type: research

Immune checkpoint inhibitor therapy in neoadjuvant and adjuvant treatment for cancer: A paradigm shift in the treatment of resectable gastrointestinal cancer 3)A paradigm shift in the treatment of colorectal cancer
AbstractImmune checkpoint inhibitors, such as anti-programmed cell death-1, programmed cell death ligand-1, and cytotoxic T-lymphocyte antigen-4 monoclonal antibodies, have been notably effective in various types of cancers. Mismatch repair deficiency and microsatellite instability-high tumors have been established as striking biomarkers for response to immune checkpoint inhibitors. These biomarkers show a higher mutational burden, have cancer-associated neoantigens, and dense immune cell infiltration, which generates a robust immune response. For metastatic colorectal cancer, pembrolizumab and nivolumab, with or without i...
Source: International Journal of Clinical Oncology - September 5, 2023 Category: Cancer & Oncology Source Type: research

Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis
ConclusionsDeveloping irAEs, particularly multiple irAEs, is associated with favourable survivals in advanced RCC patients treated with nivolumab plus ipilimumab. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - September 2, 2023 Category: Cancer & Oncology Source Type: research

Advantages and limitations of estrogen replacement therapy on hypogonadal survivors of childhood cancer
ConclusionIndividualized management strategies beyond ERT are essential to reduce long-term complications in CCS with hypogonadism, considering the type and timing of cancer treatment. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - August 30, 2023 Category: Cancer & Oncology Source Type: research

Expression of SMARCA2 and SMARCA4 in gastric adenocarcinoma and construction of a nomogram prognostic model
ConclusionThe loss of SMARCA2 and SMARCA4 correlated with poor differentiation, leading to a worse prognosis. SMARCA2, as an independent prognostic factor, combined with other clinicopathological variables, established a novel nomogram prognostic model, which outperformed the AJCC TNM model. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - August 27, 2023 Category: Cancer & Oncology Source Type: research

Meta-analysis of three randomized trials of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as first-line treatment for advanced gastric cancer
ConclusionsSP and XP were both effective and well tolerated. SP might be suitable for the pathological differentiated subtype of AGC.Clinical Trial Registration: The HERBIS-2, HERBIS-4A, and XParTS II trials were registered with UMIN-CTR as UMIN000006105, UMIN000006755, and UMIN000006045, respectively. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - August 27, 2023 Category: Cancer & Oncology Source Type: research